leadf
logo-loader
viewAequus Pharmaceuticals Inc.

Aequus and partner Medicom Healthcare win Medical Device License for Evolve Intensive Gel to treat Dry Eye Disease

The formulation will be made available in an easy-squeeze eye drop bottle containing 360 drops and no preservatives, phosphates or buffers

Aequus Pharmaceuticals Inc. - Aequus Pharmaceuticals Inc and partner Medicom Healthcare Ltd has been issued a new Medical Device License for the first of three product submissions made for the Evolve preservative free dry eye product line
The Evolve preservative-free dry eye product line can help with the symptoms of dry eye while protecting the cornea from damage

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) announced Monday that it and partner Medicom Healthcare Ltd have been issued a new Medical Device License for the first of three product submissions for the Evolve preservative-free dry eye product line. 

The Evolve Intensive Gel – a unique cross-linked combination of Carbomer 980, Hyaluronate and glycerol – provides intensive, durable hydration for patients with moderate to severe forms of Dry Eye Disease. The formulation will be made available in an easy-squeeze eye drop bottle containing 360 drops, and no preservatives, phosphates, or buffers. 

“Evolve Intensive Gel is a one-of-a-kind formulation in Canada, and is only the first of a full line of Eye Care Professional Exclusive products being launched by Aequus, that will not only improve treatment and compliance for better patient outcomes, but create an improved revenue stream for Eye Care professionals who spend additional time and resources treating dry eye patients in practice,” said Grant Larsen, chief commercial officer at Aequus, in a statement.

READ: Aequus extends commercial agreement with Sandoz for transplant therapy tacrolimus in Canada

Simon Martin, founder and CEO of UK-based Medicom Healthcare, noted that long-term use of preservatives will damage the cornea. 

“The Evolve preservative-free dry eye product line can help with the symptoms of dry eye whilst protecting the cornea from that damage,” Martin said. “Called Revive in other countries, this product is a revolutionary triple action matrix gel designed for lubrication, restoration & protection of the ocular surface, providing extended ocular residency time.”

Aequus CEO Doug Janzen added: “The Evolve line of products are going to be important revenue drivers for Aequus and we are pleased that Evolve Intensive Gel was the first approved. Launch activities for all three Evolve products are underway while the remaining two Evolve products are currently under review for approval with Health Canada.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.11 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $12.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Aequus Pharmaceuticals receives approval for Evolve Gel lubricating eye...

Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye...

on 10/19/2020

2 min read